Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Veliparib ER by AbbVie for Essential Thrombocythemia: Likelihood of Approval
Veliparib ER is under clinical development by AbbVie and currently in Phase II for Essential Thrombocythemia. According to GlobalData, Phase...
Veliparib ER by AbbVie for Polycythemia Vera: Likelihood of Approval
Veliparib ER is under clinical development by AbbVie and currently in Phase II for Polycythemia Vera. According to GlobalData, Phase...
Veliparib ER by AbbVie for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Veliparib ER is under clinical development by AbbVie and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Veliparib ER by AbbVie for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval
Veliparib ER is under clinical development by AbbVie and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid...
Veliparib ER by AbbVie for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Veliparib ER is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Veliparib ER by AbbVie for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Veliparib ER is under clinical development by AbbVie and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Veliparib ER by AbbVie for Myelofibrosis: Likelihood of Approval
Veliparib ER is under clinical development by AbbVie and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II...
Veliparib ER by AbbVie for Myeloproliferative Disorders: Likelihood of Approval
Veliparib ER is under clinical development by AbbVie and currently in Phase II for Myeloproliferative Disorders. According to GlobalData, Phase...